FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3207103941> ?p ?o ?g. }

• W3207103941 abstract "Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C.Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1-4 plus C 450 to 750 mg/m2 Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 in 21-day cycles. In Group 3, patients received AC Day 1 plus V Days 1-7, and in Group 4, AC Day 1 plus V Days 1-14 was given in 21-day cycles to evaluate effects on γH2AX foci.Eighty patients were enrolled. MTD was not reached for V and C. MTD for V and AC was V 100 mg every 12 h Days 1-4 with AC (60/600 mg/m2) Day 3 every 21 days. V PK appears to be dose-dependent and has no effect on the PK of C. Overall, neutropenia and anemia were the most common adverse events. Objective response in V and AC treated groups was 22% (11/49). Overall clinical benefit rate was 31% (25/80). PAR decreased in PBMCs. Percentage of γH2AX-positive CTCs increased after treatment with V and AC.V and AC can be safely combined. Activity was observed in patients with metastatic breast cancer." @default.
• W3207103941 created "2021-10-25" @default.
• W3207103941 creator A5000703445 @default.
• W3207103941 creator A5005424988 @default.
• W3207103941 creator A5013172168 @default.
• W3207103941 creator A5019584569 @default.
• W3207103941 creator A5020575293 @default.
• W3207103941 creator A5022891785 @default.
• W3207103941 creator A5027371881 @default.
• W3207103941 creator A5027950630 @default.
• W3207103941 creator A5034704814 @default.
• W3207103941 creator A5038468673 @default.
• W3207103941 creator A5045409088 @default.
• W3207103941 creator A5048331793 @default.
• W3207103941 creator A5053602981 @default.
• W3207103941 creator A5054371540 @default.
• W3207103941 creator A5071773606 @default.
• W3207103941 creator A5081735541 @default.
• W3207103941 date "2021-10-20" @default.
• W3207103941 modified "2023-10-16" @default.
• W3207103941 title "A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies" @default.
• W3207103941 cites W1983660130 @default.
• W3207103941 cites W1989991921 @default.
• W3207103941 cites W2019607817 @default.
• W3207103941 cites W2026262714 @default.
• W3207103941 cites W2057706543 @default.
• W3207103941 cites W2072471623 @default.
• W3207103941 cites W2074064462 @default.
• W3207103941 cites W2095798342 @default.
• W3207103941 cites W2103749099 @default.
• W3207103941 cites W2106729876 @default.
• W3207103941 cites W2119900319 @default.
• W3207103941 cites W2131670056 @default.
• W3207103941 cites W2133201432 @default.
• W3207103941 cites W2143212631 @default.
• W3207103941 cites W2281441010 @default.
• W3207103941 cites W2309983655 @default.
• W3207103941 cites W2341389059 @default.
• W3207103941 cites W2604153678 @default.
• W3207103941 cites W2741367304 @default.
• W3207103941 cites W2751119678 @default.
• W3207103941 cites W2789896032 @default.
• W3207103941 cites W2897369942 @default.
• W3207103941 doi "https://doi.org/10.1007/s00280-021-04350-x" @default.
• W3207103941 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34669023" @default.
• W3207103941 hasPublicationYear "2021" @default.
• W3207103941 type Work @default.
• W3207103941 sameAs 3207103941 @default.
• W3207103941 citedByCount "1" @default.
• W3207103941 countsByYear W32071039412022 @default.
• W3207103941 crossrefType "journal-article" @default.
• W3207103941 hasAuthorship W3207103941A5000703445 @default.
• W3207103941 hasAuthorship W3207103941A5005424988 @default.
• W3207103941 hasAuthorship W3207103941A5013172168 @default.
• W3207103941 hasAuthorship W3207103941A5019584569 @default.
• W3207103941 hasAuthorship W3207103941A5020575293 @default.
• W3207103941 hasAuthorship W3207103941A5022891785 @default.
• W3207103941 hasAuthorship W3207103941A5027371881 @default.
• W3207103941 hasAuthorship W3207103941A5027950630 @default.
• W3207103941 hasAuthorship W3207103941A5034704814 @default.
• W3207103941 hasAuthorship W3207103941A5038468673 @default.
• W3207103941 hasAuthorship W3207103941A5045409088 @default.
• W3207103941 hasAuthorship W3207103941A5048331793 @default.
• W3207103941 hasAuthorship W3207103941A5053602981 @default.
• W3207103941 hasAuthorship W3207103941A5054371540 @default.
• W3207103941 hasAuthorship W3207103941A5071773606 @default.
• W3207103941 hasAuthorship W3207103941A5081735541 @default.
• W3207103941 hasBestOaLocation W32071039412 @default.
• W3207103941 hasConcept C104317684 @default.
• W3207103941 hasConcept C112705442 @default.
• W3207103941 hasConcept C126322002 @default.
• W3207103941 hasConcept C137061746 @default.
• W3207103941 hasConcept C182979987 @default.
• W3207103941 hasConcept C185592680 @default.
• W3207103941 hasConcept C197934379 @default.
• W3207103941 hasConcept C202751555 @default.
• W3207103941 hasConcept C2776694085 @default.
• W3207103941 hasConcept C2776755627 @default.
• W3207103941 hasConcept C2777063308 @default.
• W3207103941 hasConcept C2779138821 @default.
• W3207103941 hasConcept C2781303535 @default.
• W3207103941 hasConcept C2781312401 @default.
• W3207103941 hasConcept C55493867 @default.
• W3207103941 hasConcept C71924100 @default.
• W3207103941 hasConcept C82381507 @default.
• W3207103941 hasConcept C90924648 @default.
• W3207103941 hasConcept C98274493 @default.
• W3207103941 hasConceptScore W3207103941C104317684 @default.
• W3207103941 hasConceptScore W3207103941C112705442 @default.
• W3207103941 hasConceptScore W3207103941C126322002 @default.
• W3207103941 hasConceptScore W3207103941C137061746 @default.
• W3207103941 hasConceptScore W3207103941C182979987 @default.
• W3207103941 hasConceptScore W3207103941C185592680 @default.
• W3207103941 hasConceptScore W3207103941C197934379 @default.
• W3207103941 hasConceptScore W3207103941C202751555 @default.
• W3207103941 hasConceptScore W3207103941C2776694085 @default.
• W3207103941 hasConceptScore W3207103941C2776755627 @default.
• W3207103941 hasConceptScore W3207103941C2777063308 @default.
• W3207103941 hasConceptScore W3207103941C2779138821 @default.
• W3207103941 hasConceptScore W3207103941C2781303535 @default.

• next